Byetta

DRUG3 trials

Sponsors

Bristol-Myers Squibb, Christina Kruuse

Conditions

Ischemic StrokeStrokeType 2 Diabetes

Phase 1

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes

CompletedNCT00508287

Bristol-Myers SquibbType 2 Diabetes

Start: 2007-08-31End: 2007-11-30Target: 36Updated: 2009-03-16

Phase 2

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke

Christina KruuseIschemic Stroke

Start: 2016-08-31End: 2023-11-30Target: 30Updated: 2023-03-03

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers

CompletedNCT02838589

Christina KruuseStroke

Start: 2016-08-31End: 2017-02-28Updated: 2017-02-07

Related Papers

A single dose of exenatide had no effect on blood flow velocity in the middle cerebral artery in elderly healthy volunteers: Randomized, placebo-controlled, double-blind clinical trial

Frontiers in Aging Neuroscience2022-07-253 citations